The Latest Breaking News from Teva

Teva stock catapulted Tuesday after its inflammatory bowel disease treatment showed "best-in-class potential" in a Phase 2 study.

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

Teva stock plunged Wednesday — sacrificing an earlier breakout — despite beating third-quarter expectations and raising its guidance.

The Teva Grandview GORE-TEX is an all-rounder for winter weather. Here, hiker Susan Griffin reveals why it's a must-buy this year

European Commission fines Teva over 460 million euros for improper practices related to Copaxone drug and disparagement of competitor.

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine

Institute for Fiscal Studies says increasing borrowing to fund investment ‘right thing to do’

If you like to walk and run for exercise, the Hoka Speedgoat 6 could be for you. Writer Susan Griffin reveals why you should give these colourful trainers a chance

Hiker Susan Griffin took these Ariat walking shoes for a spin around boggy marshes and uneven trails. Here's how it went - and the winning feature that makes them her favourite

The Jack Walker Lily Outdoor Shoes may not score top marks in the looks department but they are a winner in every other way. Here, Susan Griffin reviews

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…